Open-House Biologics Discount Contract 2025-06 - Pegvisomant
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No estimated contract value is provided, making it impossible to assess potential revenue.
This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until May 2027
- Provision of Pegvisomant pharmaceutical products under discount contracts
- Contract term up to 24 months from June 2025
Show full summary
Open-House procedure for pharmaceutical discount contracts (Rabattverträge) for Pegvisomant under §130a Abs. 8 SGB V. Lead buyer: Techniker Krankenkasse, with HEK and hkk as non-lead buyers. Contract runs from 01.06.2025 to 31.05.2027 (max 24 months). All qualified pharmaceutical entrepreneurs can join at any time. No estimated value or award criteria specified; procedure is non-competitive.
Risks
No estimated contract value is provided, making it impossible to assess potential revenue.
This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG for the offered medicinal product
- Must have a valid marketing authorization for the product in Germany/EU/EEA
Administrative
- Must submit self-declaration on authorization and reliability (Anlage 4 zum Vertrag)
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House Biologics Discount Contract 2025-06 - Pegvisomant
Conclusion of drug discount contracts for the active substance Pegvisomant via an Open-House procedure. No exclusivity; all eligible pharmaceutical entrepreneurs can participate.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegvisomant im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegvisomant im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 08 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 229307-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No estimated contract value is provided, making it impossible to assess potential revenue.
This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications